{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T12:52:27Z","timestamp":1792068747910,"version":"4.4.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,12]],"date-time":"2026-07-12T00:00:00Z","timestamp":1783814400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:00:00Z","timestamp":1792022400000},"content-version":"vor","delay-in-days":95,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Proteom"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1186\/s12014-026-09623-2","type":"journal-article","created":{"date-parts":[[2026,7,12]],"date-time":"2026-07-12T10:04:05Z","timestamp":1783850645000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Targeted proteomics for the detection of androgen receptor variants in preclinical models of castration-resistant prostate cancer"],"prefix":"10.1186","volume":"23","author":[{"given":"Zoi E.","family":"Sychev","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabrianne","family":"Larson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan L.","family":"Ludwig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiei","family":"Shiba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiel","family":"Tietz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua W.","family":"Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Balk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Corey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Plymate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel S.","family":"Antonarakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott M.","family":"Dehm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesse C.","family":"Seegmiller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin M.","family":"Drake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,12]]},"reference":[{"issue":"1","key":"9623_CR1","first-page":"10","volume":"75","author":"RL Siegel","year":"2025","unstructured":"Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A. Cancer statistics, 2025. CA Cancer J Clin. 2025;75(1):10\u201345.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"9623_CR2","first-page":"55","volume":"25","author":"C Stephan","year":"2014","unstructured":"Stephan C, Rittenhouse H, Hu X, Cammann H, Jung K. Prostate-specific antigen (PSA) screening and new biomarkers for prostate cancer (PCa). EJIFCC. 2014;25(1):55\u201378.","journal-title":"EJIFCC"},{"issue":"11","key":"9623_CR3","doi-asserted-by":"publisher","first-page":"18550","DOI":"10.18632\/oncotarget.14537","volume":"8","author":"KM Wadosky","year":"2017","unstructured":"Wadosky KM, Koochekpour S. Androgen receptor splice variants and prostate cancer: from bench to bedside. Oncotarget. 2017;8(11):18550\u201376.","journal-title":"Oncotarget"},{"issue":"12","key":"9623_CR4","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1038\/nrc4016","volume":"15","author":"PA Watson","year":"2015","unstructured":"Watson PA, Arora VK, Sawyers CL. Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer. Nat Rev Cancer. 2015;15(12):701\u201311.","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"9623_CR5","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1038\/pcan.2016.17","volume":"19","author":"ES Antonarakis","year":"2016","unstructured":"Antonarakis ES, Armstrong AJ, Dehm SM, Luo J. Androgen receptor variant-driven prostate cancer: clinical implications and therapeutic targeting. Prostate Cancer Prostatic Dis. 2016;19(3):231\u201341.","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"19","key":"9623_CR6","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.1200\/JCO.2016.70.1961","volume":"35","author":"ES Antonarakis","year":"2017","unstructured":"Antonarakis ES, Lu C, Luber B, Wang H, Chen Y, Zhu Y, et al. Clinical significance of androgen receptor splice variant-7 mRNA detection in circulating tumor cells of men with metastatic castration-resistant prostate cancer treated with first- and second-line abiraterone and enzalutamide. J Clin Oncol. 2017;35(19):2149\u201356.","journal-title":"J Clin Oncol"},{"issue":"2","key":"9623_CR7","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1158\/0008-5472.CAN-12-3630","volume":"73","author":"Y Li","year":"2013","unstructured":"Li Y, Chan SC, Brand LJ, Hwang TH, Silverstein KA, Dehm SM. Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines. Cancer Res. 2013;73(2):483\u20139.","journal-title":"Cancer Res"},{"issue":"5","key":"9623_CR8","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/j.eururo.2019.04.006","volume":"76","author":"A Sharp","year":"2019","unstructured":"Sharp A, Welti JC, Lambros MBK, Dolling D, Rodrigues DN, Pope L, et al. Clinical utility of circulating tumour cell androgen receptor splice variant-7 status in metastatic castration-resistant prostate cancer. Eur Urol. 2019;76(5):676\u201385.","journal-title":"Eur Urol"},{"issue":"5","key":"9623_CR9","doi-asserted-by":"publisher","first-page":"R183","DOI":"10.1530\/ERC-11-0141","volume":"18","author":"SM Dehm","year":"2011","unstructured":"Dehm SM, Tindall DJ. Alternatively spliced androgen receptor variants. Endocr Relat Cancer. 2011;18(5):R183\u201396.","journal-title":"Endocr Relat Cancer"},{"key":"9623_CR10","doi-asserted-by":"crossref","unstructured":"Zivanovic A, Miller JT, Munro SA, Knutson TP, Li Y, Passow CN, et al. Co evolution of AR gene copy number and structural complexity in endocrine therapy resistant prostate cancer. NAR Cancer. 2023;5(3):zcad045.","DOI":"10.1093\/narcan\/zcad045"},{"issue":"8","key":"9623_CR11","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1158\/1078-0432.CCR-19-3023","volume":"26","author":"Y Li","year":"2020","unstructured":"Li Y, Yang R, Henzler CM, Ho Y, Passow C, Auch B, et al. Diverse AR gene rearrangements mediate resistance to androgen receptor inhibitors in metastatic prostate cancer. Clin Cancer Res. 2020;26(8):1965\u201376.","journal-title":"Clin Cancer Res"},{"issue":"15","key":"9623_CR12","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1002\/pros.21382","volume":"71","author":"R Hu","year":"2011","unstructured":"Hu R, Isaacs WB, Luo J. A snapshot of the expression signature of androgen receptor splicing variants and their distinctive transcriptional activities. Prostate. 2011;71(15):1656\u201367.","journal-title":"Prostate"},{"issue":"14","key":"9623_CR13","doi-asserted-by":"publisher","first-page":"3457","DOI":"10.1158\/0008-5472.CAN-11-3892","volume":"72","author":"R Hu","year":"2012","unstructured":"Hu R, Lu C, Mostaghel EA, Yegnasubramanian S, Gurel M, Tannahill C, et al. Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer. Cancer Res. 2012;72(14):3457\u201362.","journal-title":"Cancer Res"},{"issue":"19","key":"9623_CR14","doi-asserted-by":"publisher","first-page":"5228","DOI":"10.1158\/0008-5472.CAN-17-0320","volume":"77","author":"JL Van Etten","year":"2017","unstructured":"Van Etten JL, Nyquist M, Li Y, Yang R, Ho Y, Johnson R, et al. Targeting a single alternative polyadenylation site coordinately blocks expression of androgen receptor mRNA splice variants in prostate cancer. Cancer Res. 2017;77(19):5228\u201335.","journal-title":"Cancer Res"},{"issue":"6","key":"9623_CR15","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1158\/0008-5472.CAN-10-1998","volume":"71","author":"Y Li","year":"2011","unstructured":"Li Y, Alsagabi M, Fan D, Bova GS, Tewfik AH, Dehm SM. Intragenic rearrangement and altered RNA splicing of the androgen receptor in a cell-based model of prostate cancer progression. Cancer Res. 2011;71(6):2108\u201317.","journal-title":"Cancer Res"},{"issue":"1","key":"9623_CR16","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1530\/EC-19-0340","volume":"9","author":"DA Dart","year":"2020","unstructured":"Dart DA, Ashelford K, Jiang WG. AR mRNA stability is increased with AR-antagonist resistance via 3\u2019UTR variants. Endocr Connect. 2020;9(1):9\u201319.","journal-title":"Endocr Connect"},{"issue":"39","key":"9623_CR17","doi-asserted-by":"publisher","first-page":"10461","DOI":"10.1073\/pnas.1706076114","volume":"114","author":"KI Takayama","year":"2017","unstructured":"Takayama KI, Suzuki T, Fujimura T, Yamada Y, Takahashi S, Homma Y, et al. Dysregulation of spliceosome gene expression in advanced prostate cancer by RNA-binding protein PSF. Proc Natl Acad Sci U S A. 2017;114(39):10461\u20136.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"13","key":"9623_CR18","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1200\/JCO.18.01731","volume":"37","author":"AJ Armstrong","year":"2019","unstructured":"Armstrong AJ, Halabi S, Luo J, Nanus DM, Giannakakou P, Szmulewitz RZ, et al. Prospective multicenter validation of androgen receptor splice variant 7 and hormone therapy resistance in high-risk castration-resistant prostate cancer: the PROPHECY study. J Clin Oncol. 2019;37(13):1120\u20139.","journal-title":"J Clin Oncol"},{"key":"9623_CR19","doi-asserted-by":"publisher","first-page":"13668","DOI":"10.1038\/ncomms13668","volume":"7","author":"C Henzler","year":"2016","unstructured":"Henzler C, Li Y, Yang R, McBride T, Ho Y, Sprenger C, et al. Truncation and constitutive activation of the androgen receptor by diverse genomic rearrangements in prostate cancer. Nat Commun. 2016;7:13668.","journal-title":"Nat Commun"},{"issue":"43","key":"9623_CR20","doi-asserted-by":"publisher","first-page":"17492","DOI":"10.1073\/pnas.1308587110","volume":"110","author":"MD Nyquist","year":"2013","unstructured":"Nyquist MD, Li Y, Hwang TH, Manlove LS, Vessella RL, Silverstein KA, et al. TALEN-engineered AR gene rearrangements reveal endocrine uncoupling of androgen receptor in prostate cancer. Proc Natl Acad Sci U S A. 2013;110(43):17492\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"9623_CR21","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1016\/j.eururo.2018.06.020","volume":"74","author":"MG Lawrence","year":"2018","unstructured":"Lawrence MG, Obinata D, Sandhu S, Selth LA, Wong SQ, Porter LH, et al. Patient-derived models of abiraterone- and enzalutamide-resistant prostate cancer reveal sensitivity to ribosome-directed therapy. Eur Urol. 2018;74(5):562\u201372.","journal-title":"Eur Urol"},{"key":"9623_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.euf.2025.03.017","author":"MG Lawrence","year":"2025","unstructured":"Lawrence MG, Keerthikumar S, Townley SL, Clark AK, Cuffe GB, Laven-Law G, et al. Reprogramming of androgen receptor activity in castration-resistant prostate cancer is shaped by truncated variants. Eur Urol Focus. 2025. https:\/\/doi.org\/10.1016\/j.euf.2025.03.017.","journal-title":"Eur Urol Focus"},{"issue":"6","key":"9623_CR23","doi-asserted-by":"publisher","first-page":"815","DOI":"10.7150\/ijbs.7.815","volume":"7","author":"Z Guo","year":"2011","unstructured":"Guo Z, Qiu Y. A new trick of an old molecule: androgen receptor splice variants taking the stage?! Int J Biol Sci. 2011;7(6):815\u201322.","journal-title":"Int J Biol Sci"},{"key":"9623_CR24","unstructured":"Virtanen T, Kwan EM, Parekh K, Bacon JVW, Huang CF, Yu IPL, et al. Repertoire and clinical hierarchy of AR locus alterations in castration-resistant prostate cancer. Ann Oncol. 2025."},{"key":"9623_CR25","unstructured":"Valentin Lopez JC, Yu C, Knutson TP, Kobilka A, Lyman J, Guo S, et al. Evolution of AR and non-AR alterations in circulating tumor DNA of metastatic prostate cancer patients treated in the phase 3 Alliance A031201 trial. Clin Cancer Res. 2026."},{"key":"9623_CR26","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/msb.2010.31","volume":"6","author":"C Lefebvre","year":"2010","unstructured":"Lefebvre C, Rajbhandari P, Alvarez MJ, Bandaru P, Lim WK, Sato M, et al. A human B-cell interactome identifies MYB and FOXM1 as master regulators of proliferation in germinal centers. Mol Syst Biol. 2010;6:377.","journal-title":"Mol Syst Biol"},{"issue":"3","key":"9623_CR27","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.ccell.2019.02.005","volume":"35","author":"A Sinha","year":"2019","unstructured":"Sinha A, Huang V, Livingstone J, Wang J, Fox NS, Kurganovs N, et al. The Proteogenomic landscape of curable prostate cancer. Cancer Cell. 2019;35(3):414\u201327.","journal-title":"Cancer Cell"},{"issue":"7","key":"9623_CR28","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1038\/nmeth.3002","volume":"11","author":"JR Whiteaker","year":"2014","unstructured":"Whiteaker JR, Halusa GN, Hoofnagle AN, Sharma V, MacLean B, Yan P, et al. CPTAC assay portal: a repository of targeted proteomic assays. Nat Methods. 2014;11(7):703\u20134.","journal-title":"Nat Methods"},{"issue":"13","key":"9623_CR29","doi-asserted-by":"publisher","first-page":"3856","DOI":"10.1158\/1078-0432.CCR-18-4276","volume":"25","author":"C Bernemann","year":"2019","unstructured":"Bernemann C, Humberg V, Thielen B, Steinestel J, Chen X, Duensing S, et al. Comparative analysis of AR variant AR-V567es mRNA detection systems reveals eminent variability and questions the role as a clinical biomarker in prostate cancer. Clin Cancer Res. 2019;25(13):3856\u201364.","journal-title":"Clin Cancer Res"},{"issue":"8","key":"9623_CR30","doi-asserted-by":"publisher","first-page":"2715","DOI":"10.1172\/JCI41824","volume":"120","author":"S Sun","year":"2010","unstructured":"Sun S, Sprenger CC, Vessella RL, Haugk K, Soriano K, Mostaghel EA, et al. Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. J Clin Invest. 2010;120(8):2715\u201330.","journal-title":"J Clin Invest"},{"issue":"1","key":"9623_CR31","doi-asserted-by":"publisher","first-page":"16734","DOI":"10.1038\/s41598-019-53139-9","volume":"9","author":"R Shizu","year":"2019","unstructured":"Shizu R, Yokobori K, Perera L, Pedersen L, Negishi M. Ligand induced dissociation of the AR homodimer precedes AR monomer translocation to the nucleus. Sci Rep. 2019;9(1):16734.","journal-title":"Sci Rep"},{"issue":"4","key":"9623_CR32","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1016\/j.cell.2016.07.007","volume":"166","author":"JM Drake","year":"2016","unstructured":"Drake JM, Paull EO, Graham NA, Lee JK, Smith BA, Titz B, et al. Phosphoproteome integration reveals patient-specific networks in prostate cancer. Cell. 2016;166(4):1041\u201354.","journal-title":"Cell"},{"issue":"24","key":"9623_CR33","doi-asserted-by":"publisher","first-page":"4261","DOI":"10.3390\/cancers16244261","volume":"16","author":"AT Arafa","year":"2024","unstructured":"Arafa AT, Ludwig M, Tuncer O, Kollitz L, Gustafson A, Boytim E, et al. Isolation of plasma extracellular vesicles for high-depth analysis of proteomic biomarkers in metastatic castration-resistant prostate cancer patients. Cancers (Basel). 2024;16(24):4261.","journal-title":"Cancers (Basel)"},{"key":"9623_CR34","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.cca.2018.08.009","volume":"486","author":"DR Bunch","year":"2018","unstructured":"Bunch DR, McShane AJ, Wang S. Investigation of transition ion ratio variation for liquid chromatography-tandem mass spectrometry: a case study approach. Clin Chim Acta. 2018;486:205\u20138.","journal-title":"Clin Chim Acta"},{"issue":"4","key":"9623_CR35","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1016\/j.molcel.2013.09.018","volume":"52","author":"CR Stumpf","year":"2013","unstructured":"Stumpf CR, Moreno MV, Olshen AB, Taylor BS, Ruggero D. The translational landscape of the mammalian cell cycle. Mol Cell. 2013;52(4):574\u201382.","journal-title":"Mol Cell"},{"issue":"1","key":"9623_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2024.115089","volume":"44","author":"L Poluben","year":"2025","unstructured":"Poluben L, Nouri M, Liang J, Chen S, Varkaris A, Ersoy-Fazlioglu B, et al. Increased nuclear factor I-mediated chromatin access drives transition to androgen receptor splice variant dependence in prostate cancer. Cell Rep. 2025;44(1):115089.","journal-title":"Cell Rep"},{"issue":"5","key":"9623_CR37","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1158\/1541-7786.MCR-23-0976","volume":"22","author":"ZE Sychev","year":"2024","unstructured":"Sychev ZE, Day A, Bergom HE, Larson G, Ali A, Ludwig M, et al. Unraveling the global proteome and phosphoproteome of prostate cancer patient-derived xenografts. Mol Cancer Res. 2024;22(5):452\u201364.","journal-title":"Mol Cancer Res"},{"issue":"6","key":"9623_CR38","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1002\/pros.23313","volume":"77","author":"HM Nguyen","year":"2017","unstructured":"Nguyen HM, Vessella RL, Morrissey C, Brown LG, Coleman IM, Higano CS, et al. LuCaP prostate cancer patient-derived xenografts reflect the molecular heterogeneity of advanced disease and serve as models for evaluating cancer therapeutics. Prostate. 2017;77(6):654\u201371.","journal-title":"Prostate"}],"container-title":["Clinical Proteomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12014-026-09623-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12014-026-09623-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12014-026-09623-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T12:19:48Z","timestamp":1792066788000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12014-026-09623-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,12]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["9623"],"URL":"https:\/\/doi.org\/10.1186\/s12014-026-09623-2","relation":{},"ISSN":["1542-6416","1559-0275"],"issn-type":[{"value":"1542-6416","type":"print"},{"value":"1559-0275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,12]]},"assertion":[{"value":"12 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"50"}}